Swiss National Bank decreased its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 648,916 shares of the medical equipment provider’s stock after selling 20,900 shares during the period. Swiss National Bank owned about 0.32% of Zimmer Biomet worth $85,313,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Welch Group LLC bought a new position in Zimmer Biomet during the third quarter worth about $78,882,000. Whitener Capital Management Inc. bought a new position in Zimmer Biomet during the third quarter worth about $109,000. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Zimmer Biomet by 5,200.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 988 shares during the period. Donaldson Capital Management LLC bought a new position in Zimmer Biomet during the third quarter worth about $205,000. Finally, Aries Wealth Management bought a new position in Zimmer Biomet during the second quarter worth about $202,000. Hedge funds and other institutional investors own 87.10% of the company’s stock.

Shares of Zimmer Biomet stock opened at $117.05 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.89 and a quick ratio of 0.96. The company has a market capitalization of $23.88 billion, a P/E ratio of 14.58, a P/E/G ratio of 2.37 and a beta of 1.16. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $134.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.03. The business had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. Zimmer Biomet’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.72 earnings per share. Equities analysts predict that Zimmer Biomet Holdings Inc will post 7.65 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend was Thursday, September 27th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.

Several research firms have recently weighed in on ZBH. Raymond James raised their price objective on shares of Zimmer Biomet from $135.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday, July 30th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Morgan Stanley raised their price objective on shares of Zimmer Biomet from $140.00 to $149.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Monday, August 27th. Finally, Jefferies Financial Group dropped their price objective on shares of Zimmer Biomet from $145.00 to $140.00 and set a “buy” rating for the company in a report on Monday, October 29th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.63.

In related news, VP Chad F. Phipps sold 30,100 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $132.37, for a total value of $3,984,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bryan C. Hanson purchased 410 shares of the stock in a transaction that occurred on Friday, August 31st. The stock was bought at an average cost of $123.03 per share, with a total value of $50,442.30. Following the acquisition, the chief executive officer now owns 25,487 shares of the company’s stock, valued at $3,135,665.61. The disclosure for this purchase can be found here. Company insiders own 0.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/19/swiss-national-bank-has-85-31-million-holdings-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.